Copyright: ©Author(s) 2026.
World J Gastrointest Pharmacol Ther. Sep 5, 2026; 17(3): 120771
Published online Sep 5, 2026. doi: 10.4292/wjgpt.120771
Published online Sep 5, 2026. doi: 10.4292/wjgpt.120771
Figure 3 Colonoscopy findings in case 2 on maintenance therapy with ustekinumab every 4 weeks and tofacitinib 5 mg twice daily - two years into deep remission.
Scarred mucosa, Mayo endoscopic score 0. A: Transverse colon; B: Sigmoid colon.
- Citation: Soldera J, Pertile MAS, Carobin LN, Brambilla DJF, Brambilla E. Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature. World J Gastrointest Pharmacol Ther 2026; 17(3): 120771
- URL: https://www.wjgnet.com/2150-5349/full/v17/i3/120771.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.120771